Skip to main content

Table 5 Onset of organ involvement among all PRESS participants during follow-up

From: Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

Visceral involvement or related outcome measure

Overall population

n (%)

Definite dcSSc

n/N (%)

At-risk for dcSSc

n/N (%)

P-value

Absolute increase in mRSS of ≥ 5 units or ≥ 25%, (n = 228)1

48 (21.1)

36/202 (17.8)

12/26 (45.2)

0.0009¶

Absolute decline of FVC % of ≥ 10%, (n = 176)1

41 (23.3)

34/153 (22.2)

7/23 (30.4)

0.3850¶

Pulmonary hypertension on RHC, (n = 296)2, 3,*

7 (2.4)

7/259 (2.7)

0/37 (0.0)

0.6021§

LVEF of ≤ 45% on TTE, (n = 189)3

5 (2.6)

5/166 (3.0)

0/23 (0.0)

1.0000§

Scleroderma renal crisis, (n = 285)3

11 (3.9)

9/248 (3.6)

2/37 (5.4)

0.6404§

All-cause mortality, (n = 301)

20 (6.6)

19/263 (7.2)

1/38 (2.6)

0.4870§

  1. mRSS, modified Rodnan Skin score; FVC, forced vital capacity; RHC, right heart catheterization; LVEF,left ventricular ejection fraction; TTE, transthoracic echocardiogram
  2. 1FVC and mRSS worsening: calculated change from baseline values
  3. 2mPAP threshold value for pulmonary hypertension was ≥25 mmHg on RHC. Participants who had PH before/at baseline were excluded from the denominator
  4. 3PH, LVEF, and scleroderma renal crisis: only counted events that occurred between the consent date and the cutoff date
  5. *Based on the results of n = 33 RHC on 29 participants
  6. ¶Chi-squared test
  7. §Fisher exact test
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us